4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MiNK Therapeutics, Inc. (INKT) operates in the Biotechnology industry and is headquartered in New York, United States with about 15 employees. Its market capitalization is roughly $57 million. In the fiscal year ended 2025-12-31, INKT reported $0M in revenue and ($12M) in net income.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($12M) | ($11M) | ($23M) | ($31M) | — |
| Net Income | ($12M) | ($11M) | ($22M) | ($28M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($3M) | ($3M) | ($3M) | ($4M) | ($2M) | — |
| Net Income | ($3M) | ($3M) | ($3M) | ($4M) | ($3M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $14M | $6M | $5M | $22M | — |
| Total Liabilities | $28M | $25M | $23M | $22M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INKT viewer.
About TickerBase · Data methodology & sources